SBIR/STTR Research Award
Therapeutic amyloid fibrils
Award amount
$220,449Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CARDINAL THERAPEUTICS INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): Accumulation of amyloid fibrils correlates with neurodegeneration in various brain diseases, but the biological role of the fibrils is unclear. Our previous experiments established that amyloidogenic peptides from thesmall heat shock protein, HspB5, and from Amyloid ? fibrils, characteristic of Alzheimer's disease, were therapeutic when administered systemically in experimental autoimmune encephalomyelitis (EAE), which models aspects of neuroinflammation in multiple sclerosis. The minimal structural units for the therapeutic amyloid fibrils are peptides as short as hexamers, which are capable of forming cross beta sheet steric zippers, but not the complex super secondary structures, torroids, cylindrins, and ? barrels,inherent in protein based amyloids that result in cellular cytotoxicity. The minimal fibrils are molecular chaperones, inhibiting protein aggregation in plasma, which reduces the gene expression of a spectrum of proinflammatory mediators. In addition,
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients